Expression, oncological and immunological characterizations of BZW1/2 in pancreatic adenocarcinoma

Jiachen Ge, Senmao Mu, Erwei Xiao, Guangjin Tian, Lianyuan Tao* and Deyu Li*

Department of Hepatobiliary Surgery, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, China

Background: Despite the progress in early diagnosis and treatment, prognosis of pancreatic adenocarcinoma (PAAD) is still poor. Basic leucine zipper and W2 domain-containing protein 1 (BZW1) and protein 2 (BZW2) are attached to the basic leucine zipper (bZIP) superfamily. Recently, BZW1 was identified as an important role in glycolysis of PAAD. However, the comprehensive reports about BZW1/2 in PAAD are not sufficient.

Methods: RNA-seq data in the Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were retrospectively analyzed. We explored the expression of BZW1/2 in PAAD tissues and the associations between BZW1/2 and prognosis. In addition, the potential roles of BZW1/2 in tumor microenvironment (TME) of PAAD were analyzed. Finally, clinicopathological data of 49 patients with PAAD in our institution were collected. Immunohistochemistry was used to determine the expression of BZW1/2 in PAAD samples.

Results: BZW1 and BZW2 were upregulated in PAAD tissues compared to normal tissues (p < 0.05). The expression of BZW1/2 were not significantly correlated with gender, grade and stage of PAAD (p > 0.05). High expression of BZW2 was an independent predictor for poor prognosis of PAAD (HR 1.834, 95%CI 1.303–2.581, p = 0.001). And a nomogram to predict overall survival (OS) of PAAD was established with a C-index of 0.685. BZW1 and BZW2 expression were positively associated with T cell mediated immune response to tumor cell and Th2 cells in xCell database. Tumor Immune Single-Cell Hub (TISCH) analyses indicated that BZW1 and BZW2 were mainly expressed in B cells and malignant cells. External cohort furtherly validated that high expression of BZW1 and BZW2 were predictors for poor prognosis of PAAD.

Conclusion: We found that BZW1 and BZW2 are highly expressed in malignant cells and B cells in the TME of PAAD. BZW2 is an independent predictor for OS of PAAD. BZW1 and BZW2 expression are positively associated with T cell mediated immune response to tumor cell and Th2 cells in PAAD.
Introduction

Current evidence suggests that the incidence of pancreatic adenocarcinoma (PAAD) has increased apparently in recent years. In the USA, PAAD has become the 10th newest cancer in men and the eighth in women (Siegel et al., 2022). Despite the progress in early diagnosis and standard treatment, the prognosis of PAAD remains poor, with a 5-year overall survival rate of about 10% (Mizrahi et al., 2020). This may be due to resistance to standard therapies, including surgery, chemotherapy and radiotherapy. With the development of precise and targeted therapy, the emerging immunotherapies might successfully improve the prognosis of PAAD (Yin et al., 2022). Given the intricacy of PAAD tumor microenvironment (TME) characterized by fibrosis and poor vascularization, the efficiency of anti-tumor therapy is probably disturbed (Truong and Pauklin, 2021).

Basic leucine zipper and W2 domain-containing protein 1 (BZW1, BZAP45) and protein 2 (BZW2, 5MP1) are important members of the basic leucine zipper (bZIP) superfamily (Mitra et al., 2001; Singh et al., 2011). BZW1 and BZW2 genes encode a 45 kDa protein containing an N-terminal bZIP domain and a C-terminal W2 domain, and are highly expressed in bronchial epithelial cells and placenta, respectively (Hiraishi et al., 2014). As a transcription factor, BZW1 is identified as a conserved regulator during the G1/S transition (Mitra et al., 2001). Moreover, BZW2 is associated with tumorigenesis maintenance and cell-cell adhesion via translation initiation and cadherin binding, respectively (Guo et al., 2014). Currently, the roles of BZW1/2 in PAAD have been largely understudied. As a paralog of BZW1, we hypothesized that BZW2 might play a similar role in the progression of PAAD. In this study, we tried to analyze the expression profiles of BZW1/2 and their immunological characteristics in PAAD samples via public database. Furthermore, PAAD tissue samples were collected and protein expression of BZW1/2 and prognosis of PAAD were analyzed in an external validation cohort.

Methods

Sample collection and pan-cancer analysis

Clinical, pathological and gene-expression data were acquired from the Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/) and Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/) databases. Patients who were diagnosed as PAAD with pathological evidence were included in this study. Samples from patients with pancreatic neuroendocrine or metastatic neoplasms were excluded from this study. Normalized pan-cancer datasets, TCGA TARGET GTEx (PANCAN, N = 19131, G = 60499), were downloaded from the UCSC database (https://xenabrowser.net/). Samples derived from solid tissue normal, primary solid tumor, normal tissue, primary blood derived cancer-bone marrow and primary blood derived cancer-peripheral blood were selected, and gene-expression data of BZW1 (ENSG00000082153) and BZW2 (ENSG00000136261) in each sample were extracted. Carcinoma sample number less than 3 was eliminated. As a result, 34 species of carcinoma were incorporated into the pan-cancer analysis.

Protein levels of BZW1/2 in PAAD samples

Immunohistochemical staining images of PAAD and normal tissues were collected from the Human Protein Atlas (HPA, https://www.proteinatlas.org/) (Colwill and Gräslund, 2011). The HPA could provide normal and pathological human tissue images stained by immunohistochemical sections. Protein levels of BZW1 and BZW2 in normal and PAAD tissues were explored in the HPA. Next, the differential expression of BZW1 and BZW2 proteins between normal and PAAD tissues was analyzed by clinical proteomic tumor or analysis consortium (CPTAC, http://ualcan.path.uab.edu/analysis-prot.html) database (Chandrashekar et al., 2017).

Roles of BZW1/2 in PAAD characteristics and prognosis

The mRNA expression data of BZW1 and BZW2 were downloaded from TCGA database. The mRNA profiles were standardized by log₂(x+0.001) transformation for further analysis. Follow-up was conducted from the data of tumor diagnosis, and the end was data of all-cause death. The recorded age, gender, grade, American Joint Committee on cancer (AJCC) stage, TNM stage, overall survival (OS) time and status of the samples were collected. Patients were grouped based on gender, grade, AJCC stage and TNM stage. The differences in BZW1 and BZW2 expression among groups were analyzed. Survival differences between the groups were also analyzed. Clinicopathological variables that were significantly correlated with prognosis were used to establish a prognostic model. An external cohort, GSE85916,
was used to validate the effects of BZW1 and BZW2 on the prognosis of PAAD patients.

**Similar gene detection analysis**

Similar gene detection module on the Gene Expression Profiling Interactive Analysis (GEPIA) website (http://gepia.cancer-pku.cn/detail.php) was used to explore genes with similar expression patterns to BZW1 and BZW2 of PAAD in TCGA dataset (Tang et al., 2017). The top 100 correlated genes of BZW1 and BZW2 were listed in descending order according to the Pearson correlation coefficient (PCC) values, which reflected the correlation intensity between variables (0.0–0.2, extremely poor; 0.2–0.4, poor; 0.4–0.6, moderate; 0.6–0.8, strong; >0.8, extremely strong).

**Functional enrichment analysis**

To better understand the potential functions of BZW1 and BZW2, Gene ontology (GO) annotations and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotations were performed by the Database for Annotation, Visualization, and Integrated Discovery (DAVID 6.8, https://david.ncifcrf.gov/). Cellular component (CC), molecular function (MF) and biological process (BP) categories were explored in GO analyses. Statistical significance was set as \( p < 0.05 \). The \( p \) values of the top five pathways were sorted in ascending order and displayed.

**Gene set variation analysis (GSVA)**

Gene lists of pancreatic cells and immune processes were acquired from Molecular Signatures Database (MSigDB v7.5.1, http://www.gsea-msigdb.org/gsea/msigdb/). We calculated the functional enrichment score of each PAAD sample. PCCs were used to evaluate the correlation between BZW1/2 expression and pancreatic cells or immune processes.

**Establishment of the protein-protein interaction (PPI) network**

It is well-established that the STRING database could be used to collect, score and integrate publicly available sources of PPI information (von Mering et al., 2005). The top 100 correlated genes were selected and incorporated to establish PPI networks. The network was constructed with a medium confidence at 0.400.

**Tumor immune single-cell hub analysis**

Tumor Immune Single-Cell Hub (TISCH, http://tisch.comp-genomics.org/home/) could provide detailed cell-type annotation at the single-cell level, and enabled the exploration of TME about different cancer types. The PAAD_CRA001160 dataset was selected to compare BZW1 and BZW2 expression in three main cell types, including immune cells, stromal cells and malignant cells. PAAD_CRA001160 dataset in TISCH contained single-cell RNA-seq of 57443 individual pancreatic cells from 35 primary PAAD patients (Peng et al., 2019).

**ESTIMATE-stromal-immune score analysis**

We further analyzed the roles of BZW1 and BZW2 in the TME. The Estimation of Stromal and Immune Cells in Malignant Tumors Tissues using Expression Data (ESTIMATE) algorithm was used to detect the fractions of infiltrating stromal and immune cells. And immune and stromal scores could be inferred by ESTIMATE algorithm. Higher immune or stromal components were associated with higher immune or stromal scores. The associations of BZW1/2 genes and ESTIMATE-Stromal-Immune score were explored.

**Tumor-infiltrating immune cell abundance analysis**

The correlations of BZW1/2 genes and tumor-infiltrating immune cell (TIIC) in PAAD samples were analyzed. The PCCs were calculated by CIBERSORT (https://cibersort.stanford.edu/), xCell (https://github.com/divirar/xCell), MCP counter (https://github.com/ebecht/MCPcounter), Estimate the Proportion of Immune and Cancer cells (EPIC, https://gellerlab.shinyapps.io/EPIC_1-1/), Tumor Immune Estimation Resource (TIMER, https://cistrome.shinyapps.io/timer/), quanTSeq (http://icbi.imed.ac.at/software/quantiseq/doc/index.html) and immunophenoscore (IPS, https://tcia.at/home). The computational methods mentioned were applied to estimate TIIC abundance in PAAD samples. The associations between BZW1/2 expression and TIIC abundance were analyzed.

**Cell lines and culture**

The human pancreatic ductal epithelium cell line HPDE6-C7 and two human pancreatic cancer cell lines, including MiaPaCa-2 and Panc-1, were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cell culture
medium was Dulbecco’s Modified Eagle Medium (DMEM) (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS) (Invitrogen). Cells (10⁵) were grown in a humidified 5% CO₂ incubator at 37°C.

**Real-time quantitative polymerase chain reaction (RT-qPCR)**

Total RNA was extracted from cell lines using TRIzol reagent (Invitrogen, USA) and reverse transcribed into cDNA via the PrimeScript RT Reagent Kit with gDNA Eraser (Takara, Japan). RT-qPCR was carried out via TB Green Premix Ex Taq II (Takara). In this respect, the RNA template and its primer were incubated at 70°C for 10min, and cooled on ice for 5min. The complex mixture was incubated at 42°C for 50min, and then heated at 70°C for 15min. The mixed reaction mixtures were amplified for 40 cycles with the following procedure, 95°C for 10s, 60°C for 10s and 72°C for 20s. Expression of mRNA was calculated by 2⁻ΔΔCt method. GAPDH was used to normalize the results of RT-qPCR. The primer sequences were as following: GAPDH, GGAGCGAGATCCCTCCAAAAT(F), GGCTGTTGTCAATCCCTGAG(F), CTGCATATCGACGGTAATCAAGT(R); BZW2, CTA TACTTCTCATGG(R); BZW1, AAGAGAGGTTTGACCCTACTCG; GAPDH, GGAGCGAGATCCCTCCAAAAT(F), GGCTGTTGTCAATCCCTGAG(F), CTGCATATCGACGGTAATCAAGT(R); BZW2, CTA TACTTCTCATGG(R); BZW1, AAGAGAGGTTTGACCCTACTCG.

**Immunohistochemistry of BZW1 and BZW2 in PAAD samples**

To further clarify the expression of BZW1 and BZW2 in PAAD samples, we retrospectively collected the clinicopathological data of 49 patients who underwent needle biopsy or radical surgery in the Department of Hepatobiliary Surgery at Henan Provincial People’s Hospital from June 2018 to May 2021. Patients were asked to receive systematic chemotherapy post-operation if circumstances permitted. After discharge, they were requested to periodic follow-up. Immunohistochemistry staining was performed to analyze the expression of BZW1 and BZW2 in tumor specimens. BZW1-(#ab85090) and BZW2-(#ab254772) antibodies were purchased from Abcam company. The EnVision two-step method was used to stain the specimen. The expression of BZW1 and BZW2 were recorded by light microscopy and evaluated by two pathologists independently. The correspondence rules of staining intensity and scoring standard were as following: uncolored, 0; light yellow, 1; yellow, 2; brown, 3. Positive expression region percentage criteria were as following: 0–30%, 0; 30–60%, 1; >60%, 2. After calculating the total points, samples were grouped into low-expression (0–2 points) and high-expression (three to five points) groups. The Pearson correlation coefficient between the two pathologists was 0.87.

**Statistical analysis**

All statistical analyses in this study were conducted by R software (version 4.1.0). Comparison analyses among expression quantities of BZW1 and BZW2 were performed by student’s t test, Mann-Whitney U test or variance analysis. The Kaplan-Meier method was used to analyze survival difference between low- and high-expression level groups. Significance of the correlation between the two groups was tested by Pearson correlation analysis. OS was calculated by the Kaplan-Meier method, and the survival differences were compared by the Log-Rank test. Univariate and multivariate Cox proportional hazards regression methods (backward selection) were used to identify clinicopathologic variables significantly associated with OS. The optimal cut-off values between low- and high-expression groups were determined by X-tile software (version 3.6.1). The PPI network was visible via Cytoscape software (version 3.9.1). R package “regplot” was used to construct the nomogram. A two-tailed p value less than 0.05 was statistically significant unless otherwise mentioned.

**Results**

**BZW1/2 were upregulated in PAAD**

Expression data about 34 types of carcinomas was acquired from the UCSC database. Mann-Whitney U test was used to make differential expression analyses. A significant expression difference of BZW1 between normal and tumor samples was observed in 28 species. Among them, up-regulated expression of BZW1 in tumor tissue was detected among 22 types of carcinomas, including GBM, GBMLGG, LGG, BRCA, CESC, LUAD, ESCA, STES, COAD, COADREAD, PRAD, STAD, LUSC, LIHC, WT, SKCM, THCA, OV, PAAD, UCS, ALL and LAML (P all <0.001). And down-regulated expression of BZW2 was detected among 6 types of carcinomas, including KIRP, KIPAN, TGCT, PCPG, ACC and KICH (Ps < 0.05, Figure 1A, Supplementary Table S1). Highly expressed BZW1 was observed in 30 species of carcinomas, including GBM, GBMLGG, LGG, UCEC, BRCA, CESC, LUAD, ESCA, STES, KIRP, KIPAN, COAD, COADREAD, PRAD, STAD, LUSC, LIHC, WT, SKCM, BLCA, READ, OV, PAAD, TGCT, UCS, ALL, LAML, ACC and CHOL (Ps < 0.05). Moreover, down-regulated expression of BZW2 in tumor tissue was detected among KIRC, THCA and KICH (Ps, Figure 1B, Supplementary Table S1). We acquired expression data of two cohorts from the GEO database, GSE28735 and GSE62452. And the results indicated...
that BZW1 and BZW2 were up-regulated in PAAD compared to normal tissues ($P$ all $<0.001$, Figures 1C,D, Supplementary Table S2). Immunohistochemistry images of BZW1 and BZW2 were obtained from the HPA website. Compared to normal tissues, BZW1 and BZW2 proteins were highly expressed in PAAD tissues using the same antibody (BZW1 antibody: HPA053272; BZW2 antibody: HPA022813) (Figures 2A–D). In the CPTAC database, expression levels of BZW1 and BZW2 in PAAD samples were significantly higher than in normal samples (Figures 2E,F).

**BZW2 was an independent predictor for OS of PAAD patients**

The relationships between BZW1/2 expression and clinicopathological parameters were investigated. The results indicated that patients with T3 stage PAAD exhibited higher expression level of BZW2 than T2 and T4 stage ($P<0.05$, Figure 3, Supplementary Table S3). In addition, BZW1 and BZW2 expression were not significantly associated with gender, grade, AJCC stage and TNM stage of
PAAD patients ($P > 0.05$, Figure 3A-I, K, L, Supplementary Table S3).

Kaplan-Meier survival analysis indicated that PAAD patients with high BZW1 and BZW2 expression had poorer OS than those with low BZW1 and BZW2 levels ($p < 0.001$ for BZW1, $p = 0.004$ for BZW2) (Figures 4A-B). GSE85916 cohort was used to validate the influences of BZW1 and BZW2 expression on prognosis. Survival analyses showed that high expression of BZW1 and BZW2 were significantly associated with short OS for PAAD patients ($p = 0.040$ for BZW1 probe 11757867_s_at, $p = 0.046$ for BZW1 probe 11744775_x_at and $p = 0.030$ for BZW2 probe 11747677_a_at) (Figures 4D-F). Univariate cox regression analysis indicated that age, grade, AJCC stage, N stage, chemotherapy, radiotherapy, BZW1 and BZW2 expression were
independent predictors for OS (Figure 5A). Multivariate cox proportional regression showed that older age (HR 1.020, 95% CI 1.001–1.040, \( p = 0.037 \)), N1 stage (HR 2.100, 95% CI 1.273–3.462, \( p = 0.004 \)), no chemotherapy (HR 2.860, 95% CI 1.846–4.433, \( p < 0.001 \)) and higher BZW2 expression (HR 1.834, 95% CI 1.303–2.581, \( p = 0.001 \)) were independently associated with poor OS (Figure 5B). A nomogram for OS of patients with PAAD was established based on these independent predictors. After adding the score corresponding to each factor, the risk score of each patient and the probability of OS longer than 180-, 365- and 1095-day could be calculated (Figure 5C). Survival probability of patients with higher risk score was significantly lower than those with lower risk score (\( p = 0.009 \), Figure 4C). This nomogram demonstrated a C index of 0.685 (95% CI 0.657–0.713). Heatmap and scatter plot indicated that the survival rate decreased with an increased risk score (Figure 5D). The receiver operator characteristic curves (ROCs) of 180-, 365- and 1095-day survival were plotted in Figure 5E.

**Similar gene analyses of BZW1/2**

Similar genes module in the GEPIA webtool was used to explore similar genes of BZW1 and BZW2 genes. The top similar 100 genes of BZW1 and BZW2 were listed in Supplementary Table S3. The top five highly correlated genes with BZW1 were BZW1P2, NAA50, KPNA4, G2E3 and RAB10 according to the PCC values. And the top five highly correlated genes with BZW2 were CBX3, NIFK, AVL9, PPIAP22 and PPIA. The
Biological function exploration

To further explore the potential biological functions of BZW1 and BZW2, we performed GO and KEGG analyses based on BZW1/2 and their similar genes. The top five enriched BP clusters of BZW1 included RNA localization, intracellular transport, establishment of RNA localization, intracellular protein transport and nucleobase containing compound transport (Figure 6A). The top five enriched MF clusters of BZW1 included RNA binding, ribonucleoprotein complex binding, arrestin family protein binding, hydrolase activity acting on acid anhydride and peptide alpha-N-acetyltransferase activity (Figure 6B). The top five enriched CC clusters of BZW1 included nuclear pore, phosphatase complex, nuclear envelop, NatA complex and nuclear protein containing complex (Figure 6C). Significantly enriched KEGG pathways involved in variations of BZW1 expression included RNA transport, protein processing in the endoplasmic reticulum, AMPK signaling pathway and mRNA surveillance pathway (Figure 6D). The top five enriched BP clusters of BZW2 included ribonucleoprotein complex biogenesis, ribosome biogenesis, peptide biosynthetic process, RNA metabolic process and peptide metabolic process (Figure 6E). The top five enriched CC clusters of BZW2 included ribonucleoprotein complex, envelope, pre-ribosome, mitochondrion and organelle inner membrane (Figure 6F). The top five enriched MF clusters of BZW2 included RNA binding, translation initiation factor activity, translation factor activity RNA binding, translation regulator activity and translation regulator activity nucleic acid binding (Figure 6G). The enriched KEGG pathways involved in variations of BZW2 expression included ribosome biogenesis in eukaryotes and spliceosome (Figure 6H).

BZW1/2 expression correlated with pancreatic cells and immune processes

During the progression and evolution of the TME, it was highly likely that interactions prevail between PAAD and normal pancreatic cell or immune processes. Hence, we tried to explore the effects of BZW1/2 genes on pancreatic cells and immune processes. GSVA was used to determine the enrichment scores
of pancreatic cells and immune processes in TCGA samples. Correlation analysis indicated that BZW1 and BZW2 expression was negatively associated with pancreas alpha cell, pancreatic polypeptide cell and epsilon cell. Moreover, BZW1 and BZW2 expression was positively associated with pancreas ductal cells. In addition, the results of correlation analysis suggested that BZW1 and BZW2 expression was negatively associated with neutrophil activation involved in the immune response but positively correlated with T cell mediated immune response to tumor cells \( (P < 0.05, \text{Figures 7A, B}) \).

Associations between BZW1/2 expression and the TME of PAAD

It was widely acknowledged that the ESTIMATE-Stromal-Immune score could be used to evaluate the composition of immune cells and stromal cells in the TME. In the present study, stromal score, immune score and ESTIMATE score of each sample were calculated. The results indicated that BZW1 expression was positively associated with stromal score and ESTIMATE score. However, BZW2 expression was be not
significantly correlated with stromal score, immune score and ESTIMATE score (Table 1 and Supplementary Figure S2).

Correlation between BZW1/2 and immune infiltration in PAAD

We further assessed the correlations between BZW1/2 expression and the types of TIICs. TIICs were evaluated by CIBERSORT, xCELL, MCPcounter, EPIC, TIMER, quanTIseq and IPS methods. These public microarray datasets were used to calculate immune infiltration score of each sample. After filtering the results using \( p > 1.0 \times 10^{-5} \), we found that BZW1 expression was negatively associated with the infiltration of basophils, CD4+ Tcm, MEP, NKT and Th1 cells, and positively associated with the presence of CLP, smooth muscle, Th2 cells, neutrophils, T cell CD8, DC, macrophages M1. Moreover, BZW2 expression was negatively correlated with hepatocytes, neurons and Tgd cells, and positively correlated with epithelial cells, keratinocytes, sebocytes, Th2 cells and macrophages M1 (Table 2, Supplementary Figure S3). These results indicated that BZW1 and BZW2 expression influenced TIICs through several pathways.

PPI network construction and TISCH analysis

To clarify the co-expression and interactions among of proteins, the PPI network was constructed based on the STRING database (Figure 8A). 18 and 11 proteins were proven to be interacted with BZW1 and BZW2, respectively. The interaction in the PPI network were shown in Supplementary Table S5. AGR3, eIF1, eIF2S2, eIF5 and SNX13 genes were interacted with both BZW1 and BZW2 at the same time. The PAAD_CRA001160 cohort in the TISCH database was used to investigate the relationships between BZW1/2 expression levels and tumor stromal cell infiltrations. Due to the heterogeneity of TME, we investigated the expression of BZW1 and BZW2 in stromal cell components. BZW1 was mainly expressed in B cells, fibroblasts and malignant cells, and BZW2 was upregulated in B cells, endothelial and malignant cells (Figures 8B,C).

Expression of BZW1/2 in pancreatic cell lines

BZW1 and BZW2 expressions were further verified through RT-qPCR in HPDE6-C7, MiaPaCa-2 and Panc-1 cell lines. The mRNA levels of BZW1 and BZW2 were significantly higher in Panc-1 and MiaPaCa-2 cell lines than in the HPDE6-C7 cell line (Figures 9A,F).

External cohort validation confirmed that BZW1/2 expression could predict OS in PAAD

49 samples were acquired as an external cohort, and all patients were successfully followed up. After immunohistochemical staining accomplished, the expression of BZW1 and BZW2 were classified as low- and high-expression based on scores of samples (Figure 9B-E, G-J). Among them, 13 and 36 patients were recognized as...
FIGURE 7
Heatmap showed BZW1/2 expression and enrichment scores of pancreatic cells and immune responses about each sample in each TCGA sample. (A) Correlation analyses between BZW1 expression and pancreatic cell or immune response enrichment scores. (B) Correlation analyses between BZW2 expression and pancreatic cell or immune response enrichment scores.

TABLE 1 Correlation of BZW1/2 expression and ESTIMATE-Stromal-Immune score (Pearson).

| Gene symbol | Stromal score | Immune score | ESTIMATE score |
|-------------|---------------|--------------|----------------|
|             | R value | p value | R value | p value | R value | p value |
| BZW1        | 0.253   | 6.57E-4   | 0.078   | 0.301   | 0.173   | 0.021   |
| BZW2        | -0.030  | 0.689   | -0.029  | 0.698   | -0.031  | 0.678   |
BZW1 high- and low-expression, respectively. 18 patients were identified as BZW2 high-expression, and 31 were low-expression. Correlations between BZW1/2 expression and clinicopathological factors of patients were listed in Supplementary Table S6. The expression of BZW1 and BZW2 showed no significant associations with age, gender, tumor location, differentiation, T stage, N stage, chemotherapy and radiotherapy. Survival analyses indicated
that N stage, BZW1 expression and BZW2 expression were independent predictors for OS in PAAD patients (Figure 10A). High expression of BZW1 and BZW2 were significantly corrected with poor prognosis (BZW1, \( p = 0.017 \); BZW2, \( p = 0.047 \)) (Figures 10B,C).

**Discussion and conclusion**

In China, PAAD ranks the sixth leading cause of cancer related deaths (Xia et al., 2022). Notwithstanding that significant inroads had been achieved in recent years,
PAAD patients still suffered poor prognoses and relatively short OS time (Xia et al., 2022). Given the insensitivity and drug-resistance, conventional therapy, which included surgery, chemotherapy and radiotherapy, often led to non-satisfactory curative effect nowadays. Targeted and immunological therapies were prized in the treatment of PAAD. Indeed, there was a long way to go for new therapies to be translated clinically. Based on publicly available tumor database, RNA-seq data could be used to search for prognostic-related genes and potential therapeutic targets. BZW1 and BZW2 were known as eukaryotic translation initiation factor 5 (eIF-5) mimic proteins (Singh et al., 2011; Loughran et al., 2018). It was reported that they shared a C-terminal W2 HEAT domain and an N-terminal bZIP domain (Aravind and Koonin, 2000; Loughran et al., 2018). In this study, we analyzed the expression levels of BZW1 and BZW2 in pan-cancer and distinct stages of PAAD based on the mrRNA-seq data from TCGA databases. Our results suggested that BZW1 and BZW2 were highly expressed in PAAD tissue compared to normal tissue. Results of RT-qPCR indicated that the expression levels of BZW1 and BZW2 in human pancreatic cancer cell lines were higher than in the human pancreatic epithelium cell line. Immunohistochemical staining showed that BZW1 was mainly located in the nucleus, while BZW2 was mainly expressed in the cytoplasm and membrane. Survival analyses indicated that BZW2 expression was an independent predictor for OS of PAAD patients. A nomogram based on BZW2 expression and clinicopathological factors was established to predict the prognosis of PAAD.

Current evidence suggested that BZW1 and BZW2 could influence the stringency of start codon selection in mammalian cells (Loughran et al., 2018). Besides, BZW1 transcripts were alternatively polyadenylated and expressed in tissue-specific pattern (Yu et al., 2006). The functions of BZW1 and BZW2 had been largely understudied until recently. BZW1 and BZW2 have been established to promote the malignant progression of several cancers. Shi et al. indicated that BZW1 overexpression could promote prostate cancer cell proliferation by regulating TGF-β/Smad pathway (Shi et al., 2021). Jin et al. showed that overexpression of BZW2 in hepatocellular carcinoma cells significantly stimulated the activation of PI3K/AKT/mTOR pathway (Jin et al., 2019). Huang et al. demonstrated that BZW2 mediated the stemness and survival of leukemia stem cells (Nachmias et al., 2022). Moreover, BZW1 and BZW2 could regulate TYK2 expression, which acted as an oncogene and a therapeutic target in acute myelocytic leukemia (Sanda et al., 2013; Nachmias et al., 2022). Li et al. indicated that BZW1 facilitated eIF2α phosphorylation and promoted internal ribosome entry site-dependent translation of HIF1α and c-Myc in PAAD samples (Li et al., 2022).

To further clarify the roles of BZW1 and BZW2 in TME of PAAD, we conducted GSVA for each sample in TCGA database. The results revealed that BZW1 and BZW2 expression positively correlated with T cell mediated immune response to tumor cell. Correlations between BZW1/2 expression and TIICs were further analyzed. BZW1 and BZW2 expression were positively correlated with Th2 cells, which might facilitate tumor growth in TME of PAAD (Piro et al., 2017). Interestingly, TISCH analyses showed that BZW1 and BZW2 might regulate TME of PAAD by targeting B cells, which were activated by Th2 cells. Moreover, BZW1 positively correlated with Stromal score and ESTIMATE score. These results may reveal the potential roles of BZW1 and BZW2 in immune TME of PAAD.

Although a significant association with the prognosis of PAAD was found, BZW1 and BZW2 expression were not significantly correlated with gender, grade, AJCC stage, N stage and M stage. These results might indicate that the expression of BZW1/2 was relatively stable during tumor progression. However, several limitations were found in this study. First, subgroup analyses were not carried out due to the relatively small sample size. Therefore, the prediction performance of BZW1/2 remained unclear among different subgroups. Second, the associations between BZW1/2 expression and immune TME were not externally validated. Furthermore, future studies should investigate the role of BZW2 in tumor growth and progression of PAAD. As
potential targets of PAAD, more experiments were needed to clarify the detailed mechanisms underlying the roles of BZW1/2 in PAAD.

In conclusion, we found that BZW1 and BZW2 were highly expressed in malignant cells and B cells in the TME of PAAD. BZW2 was an independent predictor for prognosis of PAAD. BZW1 and BZW2 expression were positively associated with T cell mediated immune response to tumor cell and Th2 cells in PAAD.

Data availability statement

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

Ethics statement

The studies involving human participants were reviewed and approved by Ethics Committee of Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University (2019 No.58). The patients/participants provided their written informed consent to participate in this study.

Author contributions

Conceptualization, JG, LT, and DL; investigation, JG and SM; visualization, EX and GT; supervision, LT and DL; validation, JG and DL; funding acquisition, LT and DL; project administration, EX and DL; software and methodology, JG and LT; resources, DL; writing—original draft preparation, JG and LT; writing—review and editing, SM and DL. All authors have read and agreed to the published version of the manuscript.

Funding

This study was supported by grants from the Joint Project of Medical Science and Technology Research Program of Henan Province (LHGJ20190577), Medical Science and Technology Research Plan of Henan Province, Project Co-built by Provincial Department (SB20190319), and Henan Province Health Science and Technology Innovation Excellent Young Talents Training Project (No. YXKC2020044).

Acknowledgments

We thank Home for Researchers editorial team (www.home-for-researchers.com) for language editing service.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer XG declared a shared parent affiliation with the author(s) to the handling editor at the time of review.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2022.1002673/full#supplementary-material

References

Aravind, L., and Koonin, E. V. (2000). Eukaryote-specific domains in translation initiation factors: Implications for translation regulation and evolution of the translation system. Genome Res. 10 (8), 1172–1184. doi:10.1101/gr.10.8.1172

Chandrashekar, D. S., Bashel, B., Balasubramanya, S., Creighton, C. J., Ponce-Rodriguez, I., Chakravarthi, B., et al. (2017). UALCAN: A portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia 19 (8), 649–658. doi:10.1016/j.neo.2017.05.002

Colwell, K., and Gräslund, S. (2011). A roadmap to generate renewable protein binders to the human proteome. Nat. Methods 8 (7), 551–558. doi:10.1038/nmeth.1607

Golob-Schwarzl, N., Puchas, P., Gogg-Kamerer, M., Weichert, W., Göppert, B., and Haybaeck, J. (2020). New pancreatic cancer biomarkers eIF1, eIF2D, eIF3C and eIF6 play a major role in translational control in ductal adenocarcinoma. Anticancer Res. 40 (6), 3109–3118. doi:10.21873/anticancerres14292

Guo, Z., Neilson, L. J., Zhong, H., Murray, P. S., Zanivan, S., and Zaidel-Bar, R. (2014). E-cadherin interaction complexity and robustness resolved by quantitative proteomics. Sci. Signal. 7 (354), re7. doi:10.1126/scisignal.2005473

Hiraishi, H., Oatman, J., Haller, S. L., Blunk, L., McGivern, B., Morris, J., et al. (2014). Essential role of eIF5-mimic protein in animal development is linked to control of ATF4 expression. Nucleic Acids Res. 42 (16), 10321–10330. doi:10.1093/nar/gkt5670

Huang, L., Chen, S., Fan, H., Au, F., and Sheng, W. (2020). BZW2 promotes the malignant progression of colorectal cancer via activating the ERK/MAPK pathway. J. Cell. Physiol. 235 (5), 4834–4842. doi:10.1002/jcp.29361
Jackson, R. J., Hellen, C. U., and Pestova, T. V. (2010). The mechanism of eukaryotic translation initiation and principles of its regulation. *Nat. Rev. Mol. Cell Biol.* 11 (2), 113–127. doi:10.1038/nrm2838

Jin, X., Liao, M., Zhang, L., Yang, M., and Zhao, J. (2019). Role of the novel gene BZW2 in the development of hepatocellular carcinoma. *J. Cell. Physiol.* 234, 16592–16600. doi:10.1002/jcp.2833

Li, Z., Ge, Y., Dong, J., Wang, H., Zhao, T., Wang, X., et al. (2022). BZW1 facilitates glycolysis and promotes tumor growth in pancreatic ductal adenocarcinoma through potentiating eIF2α phosphorylation. *Gastroenterology* 162 (4), 1256–1271.e14. doi:10.1053/j.gastro.2021.12.249

Loughran, G., Firth, A. E., Atkins, J. F., and Ivanov, I. P. (2018). Translational autoregulation of BZW1 and BZW2 expression by modulating the stringency of start codon selection. *PLoS ONE* 13 (2), e0192648. doi:10.1371/journal.pone.0192648

Mitra, P., Vaughan, P. S., Stein, J. L., Stein, G. S., and van Wijnen, A. J. (2001). Puriﬁcation and functional analysis of a novel leucine-zipper/nucleotide-fold protein, BZAP45, stimulating cell cycle regulated histone H4 gene transcription. *Biochemistry* 40 (35), 10693–10699. doi:10.1021/bi010529o

Mizrahi, J. D., Surana, R., Valle, J. W., and Shroff, R. T. (2020). Pancreatic cancer. *Lancet* 395 (10242), 2008–2020. doi:10.1016/S0140-6736(20)30974-0

Nachmias, B., Khan, D. H., Vossin, V., Mer, A. S., Thomas, G. E., et al. (2022). IPO11 regulates the nuclear import of BZW1/2 and is necessary for AML cells and stem cells. *Leukemia* 36 (5), 1283–1295. doi:10.1038/s41375-022-01513-4

Peng, J., Sun, B. F., Chen, C. Y., Zhou, J. Y., Chen, H., et al. (2019). Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. *Cell Res.* 29 (9), 725–738. doi:10.1038/s41422-019-0193-y

Piro, G., Simionato, F., Carbone, C., Frizziero, M., Malleo, G., Zanini, S., et al. (2017). A circulating T(H)1 cytokine proﬁle predicts survival in patients with resectable pancreatic adenocarcinoma. *Oncoimmunology* 6 (9), e1322424. doi:10.1080/2162408X.2017.1322242

Sandá, T., Tyner, J. W., Gutierrez, A., Ngo, V. N., Glover, J., Chang, B. H., et al. (2013). TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. *Cancer Discov.* 3 (5), 564–577. doi:10.1158/2159-8290.CD-12-0504

Shi, Z., Xiao, C., Lin, T., Wu, J., and Li, K. (2021). BZW1 promotes cell proliferation in prostate cancer by regulating TGF-β1/Smad pathway. *Cell Cycle* 20 (9), 894–902. doi:10.1080/15384101.2021.1909242

Siegel, R. L., Miller, K. D., Fuchs, H. E., and Jemal, A. (2022). Cancer statistics, 2022. *CA. Cancer J. Clin.* 72 (1), 7–33. doi:10.3322/caac.21708

Singh, C. R., Watanabe, R., Zhou, D., Jennings, M. D., Fukao, A., Lee, B., et al. (2011). Mechanisms of translational regulation by a human eIF3-mimic protein. *Nucleic Acids Res.* 39 (19), 8314–8328. doi:10.1093/nar/gkr339

Tang, Z., Li, C., Kang, B., Gao, G., Li, C., and Zhang, Z. (2017). GEPIA: A web server for cancer and normal gene expression proﬁling and interactive analyses. *Nucleic Acids Res.* 45 (W1), W98–W102. doi:10.1093/nar/gkw247

Truong, I. H., and Pauklin, S. (2021). Pancreatic cancer microenvironment and cellular composition: Current understandings and therapeutic approaches. *Cancers* (Basel) 13 (19), 5028. doi:10.3390/cancers13195028

von Mering, C., Jensen, L. J., Snel, B., Hooper, S. D., Krupp, M., Foglierini, M., et al. (2005). STRING: known and predicted protein-protein associations, integrated and transferred across organisms. *Nucleic Acids Res.* 33, D433–D437. doi:10.1093/nar/gkx055

Xia, C., Dong, X., Li, H., Gao, M., Sun, D., He, S., et al. (2022). Cancer statistics in China and United States, 2022: proﬁles, trends, and determinants. *Chin. Med. J.* 135 (5), 584–590. doi:10.1097/CM9.0000000000002108

Yin, C., Alqhtani, A., and Noél, M. S. (2022). The next frontier in pancreatic cancer: Targeting the tumor immune milieu and molecular pathways. *Cancers* (Basel) 14 (11), 2619. doi:10.3390/cancers14112619

Yu, M., Sha, H., Gao, Y., Zeng, H., Zhu, M., and Gao, X. (2006). Alternative 3′ UTR polyadenylation of Bzw1 transcripts display differential translation efﬁciency and tissue-speciﬁc expression. *Biochem. Biophys. Res. Commun.* 345 (1), 479–485. doi:10.1016/j.bbrc.2006.04.113